A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs RC 48 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors RemeGen
- 20 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018.
- 20 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 16 Sep 2016 New trial record